UPDATE: Replimune (REPL) - The Clock Is Set
PDUFA August 2, AdCom in Late July, and the Binary-Event Name Gets a Date
Executive Summary
On June 1, I wrote that “the next clean entry signal is FDA acceptance and a PDUFA date — that’s the moment the regulatory tail is genuinely retired, and the moment the equity stops being a binary-event name and starts being a launch-execution name.” The agency just delivered exactly that — with a twist.
Today’s update confirms the FDA has accepted the RP1 + nivolumab BLA resubmission as a complete, class 1 response with a PDUFA goal date of August 2, 2026. The company has also been notified to expect an advisory committee meeting in late July. The stock has run from $9.00 on June 1 to $11.63 today — +29.2% in 18 trading days — and the market is now pricing a five-week sprint to a binary outcome that just got a calendar attached to it.
This is the regulatory tail being formally pinned down. It is not yet retired.
The Receipts
Class 1 acceptance, PDUFA August 2, 2026. A Class 1 designation means the FDA considers the resubmission a complete response to the CRL — the same Class 1 framing they used when accepting the original resubmission in October 2025. The two-month review clock (vs. the six-month Class 2 clock) is the FDA telegraphing that the package is responsive on its face. The implication: the May 29 “willingness to prioritize” posture is now a binding goal date. The agency has put its name on a calendar.
Late July AdCom. This is the new wrinkle. The April CRL and the May 29 reversal both happened without an advisory committee. Convening one now — with five weeks between the meeting and the goal date — means the FDA wants external oncology expert cover for whatever it decides. Why it matters: AdComs are double-edged. A positive vote on a single-arm package would be the strongest possible regulatory tailwind RP1 could get; a negative vote would be very hard to overcome by August 2. The AdCom is now the dominant near-term catalyst, not the PDUFA itself.
The label question shifts from “if” to “what.” The accelerated-approval ask is unchanged: RP1 + nivolumab in patients with confirmed progression on an anti–PD-1 containing regimen — the same anti-PD-1–failed advanced melanoma population from IGNYTE. With ~112,000 new U.S. melanoma cases annually and ~8,500 deaths, ~50% of patients failing PD-1 therapy, the unmet-need framing is doing real work in the resubmission narrative.
What’s NOT in the release. Still no mention of new randomized data, no IGNYTE-3 interim substitution, no label-scope modifications. The package the AdCom will see is, as best I can tell, the IGNYTE single-arm data plus the 32.9-month median OS, 47.8% 3-year survival, 83.5% responder 3-year survival ASCO update I broke down on June 1. That’s the same package — but now with an FDA that has agreed to put it in front of a panel.
The Scientific Reality Check
The AdCom is where the depth-and-durability story I wrote about three weeks ago has to do real work. The IGNYTE topline — 33.6% ORR vs. ~11.5% historical control, 24.8-month median DOR — is what twice got called “not considered to be an adequate and well-controlled clinical investigation.” The 3-year landmark OS update is the rebuttal: a median OS of 32.9 months in a population whose historical mOS sits in the ~8–10 month range, with the subgroup robustness (disease stage, PD-L1 status, prior CTLA-4, primary vs. secondary PD-1 resistance) that addresses the original CRL’s “heterogeneity” complaint head-on.
The panel question to anticipate: does a long-tail OS curve and a clean subgroup story compensate for the absence of randomization in a setting where, per the company’s framing, IGNYTE-3 interim OS isn’t until 2H 2027? That’s a values question wrapped in a statistics question, and AdComs decide values questions all the time. The fact that the FDA convened a panel rather than approving or rejecting on its own suggests the agency wants the medical community to share the call — which, in itself, is a softer posture than the April CRL implied.
On RP2, nothing has changed since the ASCO readout — the platform optionality (uveal melanoma randomized Phase 2/3, HCC monotherapy data end of 2026, the ARTACUS solid-organ-transplant niche) is still attached to the equity but is not part of the August decision.
The Risks Still on the Table
The AdCom can go badly. A negative panel vote in late July would be very difficult to recover from in the five weeks before August 2. ODAC and similar oncology panels have been historically tough on single-arm accelerated-approval packages, and the FDA’s own Project FrontRunner posture is the doctrinal headwind. The 3-year OS data helps; it does not eliminate the structural concern.
The label can still be narrow. Even an approval could carve the indication tighter than the ~10,000-patient anti–PD-1–failed melanoma TAM I outlined in February. Watch for restrictions on prior-therapy criteria, disease stage, or lesion accessibility.
The price has run. The stock has roughly tripled from the April CRL low of $4.76, and is now ~29% above where it sat on the morning I wrote the ASCO update. The asymmetry that was present at $4.76 — and still meaningfully present at $8.69 — has compressed materially. Anyone entering here is paying for the AdCom date and the Class 1 acceptance, both of which are now public information.
Cash is still the post-restructuring question mark. December 31, 2025 cash was $269.1M with runway “into Q1 2027” — before the April severance and manufacturing scale-back charges. A capital raise into a pre-AdCom rally would not surprise me; with the stock at $11.63, it would also be the rational thing for management to do.
The Updated Verdict
Current Stance: SPECULATIVE BUY (HOLD INTO ADCOM/PDUFA).
The rationale:
The catalyst path has gone from posture to calendar. The PDUFA date is August 2, 2026; the AdCom is late July. The thing I told readers to watch for has happened.
The Class 1 acceptance is a procedural positive — the FDA does not assign a two-month clock to a package it considers deficient on its face. That’s a meaningful tell about how the agency views the resubmission’s responsiveness, separate from whether it will ultimately approve.
The AdCom is now the dominant risk. A favorable panel vote likely guarantees approval; an unfavorable one likely guarantees a third CRL. Position sizing should reflect that the next ~five weeks contain a binary inside a binary.
The +29% run since June 1 means the easy de-risking trade is done. Fresh entries here are paying for information the market now also has.
For those who took the May 29 re-entry near $4.76–$8.69: this is the moment the original setup pays off on paper, and a moment where trimming into the AdCom — or hedging with puts whose IV will inflate as the panel date approaches — looks like reasonable risk management rather than abandonment of thesis. For those still on the sidelines: chasing a tripled stock into a late-July AdCom is the kind of trade that only works if the panel votes the way the company needs it to. The asymmetric setup is gone; what remains is a five-week countdown to a yes/no.
The agency has signaled willingness, set a date, and called a panel. It still has not signaled approval. Size accordingly.
This post is for informational and educational purposes only and does not constitute investment advice or a recommendation to buy or sell any securities. The author is a medicinal chemist, not a licensed financial advisor; the scientific analysis herein should not be interpreted as medical guidance. Biotech investing is inherently volatile — past scientific validation and early clinical data do not guarantee future late-stage clinical success or regulatory approval. Do your own due diligence.